EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Host immune responses to gene therapy: when the immune system meets genetic medicine

Roberto Nitsch

Frontiers in Medicine · 13.11.2026 · 13

DOI: 10.3389/fmed.2026.2006852 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Medicine, online erschienen am 13.11.2026. Verfasst von Roberto Nitsch. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In order to exert its therapeutic function, gene therapy needs the host's immune system to tolerate something that it has naturally evolved to notice. Namely, viral particles, synthetic nanoparticles, foreign nucleic acids, newly expressed proteins, or even worse, a creative combination of all the above. Immune recognition is therefore not an unexpected complication of genetic medicine, like some might wrongly believe, but an intrinsic part of its pharmacology. The clinical consequences, however, vary enormously. Innate responses and complement activation can produce acute inflammatory reactions, whereas antibodies and T-cell responses can restrict therapeutic components’ availability, eliminate transduced cells, reduce durability, or make redosing difficult if not impossible. These effects depend not only on the delivery vehicle, but also on cargo, dose, route of administration, target tissue, manufacturing features, and the patient's immunological status and immune history. Here, we provide a concise and critical overview of host responses to viral and non-viral gene therapies, with adeno-associated virus and lipid nanoparticles as the principal clinical examples, and discuss therapeutic proteins and genome editors as additional immunogenic layers. We then focus on what has actually been observed in patients, including transaminitis, complement-associated thrombotic microangiopathy, infusion reactions and selected severe or fatal events. Importantly, gene-therapy toxicity and immunogenicity are not interchangeable concepts. The emerging clinical picture instead supports a more useful view: immune risk is heterogeneous, increasingly mechanistically tractable, and potentially manageable through patient selection, product engineering, dose and route optimization, monitoring and targeted immunomodulation.

Zitieren

APA

Nitsch, R. (2026). Host immune responses to gene therapy: when the immune system meets genetic medicine. Frontiers in Medicine, 13. https://doi.org/10.3389/fmed.2026.2006852

Vancouver

Nitsch R. Host immune responses to gene therapy: when the immune system meets genetic medicine. Frontiers in Medicine. 2026;13. doi:10.3389/fmed.2026.2006852

BibTeX
@article{Nitsch2026,
  author = {Nitsch, Roberto},
  title = {Host immune responses to gene therapy: when the immune system meets genetic medicine},
  journal = {Frontiers in Medicine},
  year = {2026},
  volume = {13},
  doi = {10.3389/fmed.2026.2006852}
}
Kostenlos starten →